AGENDA
Translational Advances in Cancer Prevention Agent Development
Sponsored by the Division of Cancer Prevention, National Cancer Institute
and the Office of Disease Prevention
National Institutes of Health
Bethesda, MD 20892
DATE: August 27-29, 2020
Day 1 Morning Session (8:00 to 12:00)
7:00-8:00 AM Registration (Please allow sufficient time to go through security)
8:00-8:30 AM Welcome Remarks
Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI
Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI
8:30-9:30 AM Translational Research Plenary Speaker
Raymond DuBois, M.D., Ph.D., Medical University of South Carolina
Inflammation and inflammatory mediators as targets for cancer prevention/interception
Session I*
Advances in Small Molecule Agent Development
Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.
9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center
Estrogen metabolism: A target for intervention in non-small cell lung cancer
10:00-10:30 AM Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center
Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters
10:30-10:50 AM Break
10:50-11:20 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio
Cancer and aging prevention by mTOR inhibition
11:20-11:50 AM Speaker 4: Karen Liby, Ph.D., Michigan State University
Targeting the immune system for the prevention of Kras-driven cancers
11:50-1:15 PM Lunch
Day 1 Afternoon Session (1:15 to 4:30)
Session II
Advances in Immunomodulatory Agent Development
Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.
1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota
A STAT3 decoy for lung cancer prevention
1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School
Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial
2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia
CD137 immune checkpoint pathway as an effective target for cancer immunoprevention
2:45-3:00 PM Break
3:00-3:30 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital
Epithelium-derived alarmins role in breast cancer immunoprevention
3:30-3:50 PM NCI PREVENT Preclinical Drug Development Program
Mark Miller, Ph.D., Division of Cancer Prevention, NCI
Q&A Session until 4:30 PM
4:30-6:00 PM Poster Session
Day 2 Morning Session (9:00 to12:00)
Session III
Alternative Dosing and Combination Strategies to Reduce Toxicity
Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.
9:00-9:30 AM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center
Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer
9:30-10:00 AM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University
Location, location, location: oral cancer chemoprevention by local delivery
10:00-10:30 AM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma
Safer chemopreventive approaches to colonic adenoma prevention
10:30-10:45 AM Break
10:45-11:15 AM Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics
Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427
11:15-11:45 AM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center
Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP
11:45-1:00 PM Lunch
Day 2 Afternoon Session (1:00 to 4:00)
Session IV
Emerging Vaccines for Cancer Prevention
Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.
1:00-1:30 PM Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University
Immunoprevention for Lynch Syndrome
1:30-2:00 PM Speaker 2: Mary (Nora) Disis, M.D., University of Washington
Vaccines targeting cancer initiation associated proteins
2:00-2:30 PM Speaker 3: Richard Roden, Ph.D., Johns Hopkins University
Development of vaccines for broad protection against and elimination of HPV infection
2:30-2:50 PM Break
2:50-3:20 PM Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh
MUC1 vaccine for prevention of colorectal adenoma
3:20-3:50 PM Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center
Development of a Kras preventive vaccine
4:00-6:00 PM Poster Session
Day 3 Morning Session (8:00 to 12:00)
8:00-9:00 AM Clinical Research Plenary Speaker
Powel Brown, M.D., Ph.D., MD Anderson Cancer Center
Novel cancer prevention strategies in the molecular era
Session V
Cancer Prevention Clinical Trials
Co-Chairs: Peter Allen and Eva Szabo
9:00-9:15 AM Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Eva Szabo, M.D., Division of Cancer Prevention, NCI
Q&A to 9:30 AM
9:30-10:00 AM Speaker 1: Peter Allen, M.D., Duke University
Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?
10:00-10:30 AM Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center
Cancer immune-interception for Lynch Syndrome
10:30-10:50 AM Break
10:50-11:20 AM Speaker 3: Seema Khan, M.D., Northwestern University
Local transdermal drug delivery to the breast for cancer prevention
11:20-11:50 AM Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital
Novel strategies for aspirin prevention of cancer
12:00 PM Adjourn
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| File Title | Fast Track’s |
| Subject | With Examples |
| Author | NCI PRA OMB Team |
| File Modified | 0000-00-00 |
| File Created | 2022-02-01 |